Company History | Corporate Profile | Boehringer Ingelheim US Company History | Corporate Profile | Boehringer Ingelheim US Click here to watch our video on the history of Boehringer Ingelheim, founded by Albert Boehringer in 1885.
Boehringer’s unique approach to innovation Boehringer’s unique approach to innovation Boehringer’s unique approach to driving patient-centric innovation
Brigitte Fuhr Brigitte Fuhr Brigitte Fuhr, Head of Central Data Science, is working on a global program that will transform our ability to develop breakthrough treatments.
Boehringer Ingelheim and Tsinghua University Team up to Develop Novel Treatment Approaches that Rally the Immune System Against Infectious Diseases Boehringer Ingelheim and Tsinghua University Team up to Develop Novel Treatment Approaches that Rally the Immune System Against Infectious Diseases Boehringer Ingelheim and Tsinghua University Team up to Develop Novel Treatment Approaches that Rally the Immune System Against Infectious Diseases
Boehringer Ingelheim enters into collaboration with Roche to partner for inflammatory bowel diseases Boehringer Ingelheim enters into collaboration with Roche to partner for inflammatory bowel diseases Boehringer Ingelheim enters into collaboration with Roche to partner for inflammatory bowel diseases
We’re investing $50 million in Puerto Rico. It will increase our ability to make products to protect pets. We’re investing $50 million in Puerto Rico. It will increase our ability to make products to protect pets. We’re investing $50 million in Puerto Rico. It will increase our ability to make products to protect pets.
Positive results reported in HER2 mutated lung cancer Positive results reported in HER2 mutated lung cancer Boehringer’s zongertinib shows encouraging efficacy and tolerability profile in previously treated HER2 mutated lung cancer patients
Partnering in Retinal Health Partnering in Retinal Health Our partnering interests in retinal diseases offer opportunities for collaboration to complement our pipeline and advance treatment and delivery.
Our Respiratory Partnering Interests Our Respiratory Partnering Interests Our Respiratory Partnering Interests
Our Immunology Partnering Interests Our Immunology Partnering Interests Our Immunology Partnering Interests
Our Technology Partnering Interests Our Technology Partnering Interests Our Technology Partnering Interests
Boehringer Ingelheim bolsters biologics research and development with 230 million euro investment in new development center Boehringer Ingelheim bolsters biologics research and development with 230 million euro investment in new development center Boehringer Ingelheim bolsters biologics research and development with 230 million euro investment in new development center
Our Retinal Health Partnering Interests Our Retinal Health Partnering Interests Our Retinal Health Partnering Interests
Our Biotherapeutic Technology Partnering Interests Our Biotherapeutic Technology Partnering Interests Our Biotherapeutic Technology Partnering Interests
Cardiometabolic Diseases Cardiometabolic Diseases We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in CardioMetabolic diseases.
Oncology & Cancer Immunology Oncology & Cancer Immunology We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in oncology.
Our Research Beyond Borders Partnering Interests Our Research Beyond Borders Partnering Interests Our Research Beyond Borders Partnering Interests
Our Central Nervous System Partnering Interests Our Central Nervous System Partnering Interests Our Central Nervous System Partnering Interests
Boehringer Ingelheim Acquires AMAL Therapeutics Boehringer Ingelheim Acquires AMAL Therapeutics Boehringer Ingelheim Acquires AMAL Therapeutics